Free Trial

Inari Medical Q2 2023 Earnings Report

Inari Medical logo
$56.16 -0.59 (-1.04%)
(As of 12/17/2024 ET)

Inari Medical EPS Results

Actual EPS
$0.04
Consensus EPS
-$0.14
Beat/Miss
Beat by +$0.18
One Year Ago EPS
-$0.19

Inari Medical Revenue Results

Actual Revenue
$119.01 million
Expected Revenue
$116.67 million
Beat/Miss
Beat by +$2.34 million
YoY Revenue Growth
+28.30%

Inari Medical Announcement Details

Quarter
Q2 2023
Time
After Market Closes

Conference Call Resources

Conference Call Audio

Uncover the Top Gold Stock of the Bull Market (Ad)

Gold Stocks Are Surging—Is West Red Lake Gold Mines Your Next Profit Play?

Click here to see how this opportunity could transform your portfolio.

Inari Medical Earnings Headlines

Inari Medical initiated with an Outperform at Oppenheimer
Trump’s Secret Manhattan Project
On January 20, a whole new Manhattan Project is set to begin: Trump’s Manhattan Project. Folks, I just spent six months investigating this...and what I found is shocking.
Demystifying Inari Medical: Insights From 6 Analyst Reviews
See More Inari Medical Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Inari Medical? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Inari Medical and other key companies, straight to your email.

About Inari Medical

Inari Medical (NASDAQ:NARI) builds minimally invasive, novel, and catheter-based mechanical thrombectomy devices and accessories for the specific disease states in the United States. The company provides ClotTriever system, which is designed to core, capture, and remove large clots from large vessels for treatment of deep vein thrombosis and peripheral thrombus; FlowTriever system, a large bore catheter-based aspiration and mechanical thrombectomy system to remove large clots from large vessels in the peripheral vasculature for treating pulmonary embolism and other complex venous thromboembolism cases; InThrill system to treat small vessel thrombosis; and LimFlow system for patients who have chronic limb-threatening ischemia with no suitable endovascular or surgical revascularization options and risk of major amputation. It serves interventional radiologists, interventional cardiologists, and vascular surgeons. The company was formerly known as Inceptus Newco1 Inc. and changed its name to Inari Medical, Inc. in September 2013. Inari Medical, Inc. was incorporated in 2011 and is headquartered in Irvine, California.

View Inari Medical Profile

More Earnings Resources from MarketBeat

Upcoming Earnings